News › Clinical Practice, Industry News, Patient Care

Allergan Receives FDA Approval for Juvéderm Voluma XC for Mid-face Injection via Cannula

September 11, 2019

Allergan plc has announced it received U.S. Food and Drug Administration (FDA) approval for the use of Juvéderm Voluma XC, a hyaluronic acid gel dermal filler, with a TSK Steriglide cannula for cheek augmentation to correct age-related volume deficit in the mid-face in adults over 21. A cannula is a thin, flexible tube with a rounded tip that can serve as an effective delivery system. Use of a cannula allows for injection of Juvéderm Voluma XC in the cheek area. The TSK Steriglide has a unique design compared to other cannulas available on the market and features a patented tip design with a near-tip delivery port for precise product placement.
Read more at PR Newswire >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Galderma to Acquire ZO Skin Health for $1.5 Billion
    • AscendPoint Agency Acquires Medical Marketing Whiz
    • PracticeQ Becomes Platinum Vendor Affiliate with the American Med Spa Association
    • Fresh Clinics Acquires Spakinect
    • Arkansas Nursing Board Comment Deadline Approaching for Medical Aesthetics and IV Hydration Guidance
Advertisement